ANTIRNA Selected for a Presentation at BARDA Industry Day, Lightning Talk 2021

September 18, 2021:

Antirna Inc. Burlington MA, a Massachusetts based start-up biotech company that uses a small molecules approach to develop innovative broad-spectrum antiviral drugs, announces that it has been selected to present its first-in-class antiviral candidates “Carbocyclic Nucleosides As Broad-Spectrum Antiviral for COVID-19” at BARDA Industry Day 2021, in on November 3-4.

The BARDA Industry Day is the annual event dedicated to biological risk, whether of natural origin, accidental or intentional. At this congress, the BARDA presents the U.S. Government medical countermeasure priorities, and updates on the actions taken and the results obtained. The Lightning Talks, organized during this congress, are companies and research organizations pitching on medical innovations that can contribute to the protection against biological risks.

Antirna Incorporated is one of the very few small drug development companies selected for the Lightning Talks and will discuss “Carbocyclic Nucleosides As Broad-Spectrum Antiviral for COVID-19.”

“We are very proud to have been selected for this event. The selection process is drastic, and we are one of the few startup companies pitching at the Lightning Talks this year. The “Carbocyclic Nucleosides As Broad-Spectrum Antiviral for COVID-19” are of interest to the audience of high-level scientists, military and industry specialists, as well as funding agencies. This is a great opportunity to provide visibility to our antiviral candidate,” says Dr. Suhaib Siddiqi, CEO of Antirna Incorporated.

Our lead candidate from Carbocyclic Nucleosides class of molecules is a broad-spectrum synthetic antiviral, which specifically targets various respiratory viruses.

ABOUT BARDA AND BARDA INDUSTRY DAY

Biomedical Advanced Research and Development Authority (BARDA), part of the HHS4 Office of the Assistant Secretary for Preparedness and Response, was established to aid in securing the United States from chemical, biological, radiological, and nuclear (CBRN) threats, as well as from COVID-19, pandemic influenza (PI) and emerging infectious diseases (EID). BARDA supports the transition of medical countermeasures such as vaccines, drugs, and diagnostics from research through advanced development towards consideration for approval by the FDA and inclusion into the Strategic National Stockpile. BARDA’s support includes funding, technical assistance, and core services, ranging from a clinical research organization network to Centers for Innovation in Advanced Development and Manufacturing, and a fill-finish manufacturing network. To-date, BARDA has supported 42 FDA approvals for products addressing CBRN, PI, and EID threats.

The BARDA annual Industry Day 2019 conference on U.S. government medical countermeasures is taking place on 15-16 October 2019 in Washington, D.C. BARDA Industry Day brings together over 1,000 participants to exchange information about the government’s needs, and industry’s technologies, capabilities, and products that can fill those needs. BARDA will brief on program priorities and talk with public and private sector colleagues on developing medical countermeasures. Lightning Talks (November3-4) will showcase innovative discoveries and will be brief, energetic, and full of information for attendees and prospective partners.

ABOUT ANTIRNA

Antirna is a startup company, a leader in disruptive innovation, which aims to help meet the challenges of antiviral resistance and the transition to a sustainable production model for the antiviral industries.

ANTIRNA is developing unique and comprehensive expertise in the field of virology that it can decipher, culture, and optimize to disclose unsuspected possibilities and induce them to produce biobased molecules with activities of interest on an industrial scale.

Contacts

Investors
Suhaib Siddiqi, Ph.D.
Antirna Inc.
Ph.: +1 (339) 234-0859
ssiddiqi@antirna.com